Breaking Finance News

A statement released earlier today by Chardan Capital about Novavax (NASDAQ:NVAX) lowers the target price to $1.50

Only yesterday Novavax (NASDAQ:NVAX) traded 15.50% higher at $1.49. The company’s 50-day average is $7.01 and its 200-day average is $6.21. With the last stock close down 76.02% relative to the two hundred day moving average, compared to the S&P 500 Index which has fallen -0.01% over the same period. Trading volume was was up over the average, with 82,929,252 shares of NVAX changing hands over the typical 9,895,760 shares..

In a report issued 9/20/2016 Chardan Capital dropped the target price of Novavax (NASDAQ:NVAX) from $6 to $2 stating a possible upsideof 0.01%.

On 9/16/2016, FBR & Co. reported about Novavax(NASDAQ:NVAX) dropped the target price from $17.00 to $12.00 that indicated a possible upside of 7.57%.

Performance Chart:


A total of 8 firms have reported on NVAX. Five firms rate the company a strong buy, three firms rate the company a buy, 0 analysts rate the company a hold, 0 rate the stock to underperform, and finally 0 brokeragesrate the stock as sell with a 12-month target stock price of $15.39

With a market cap of $0.0, Novavax has a one-year low of $1.16 and a one-year high of $9.97 with a PE ratio of 0.

More About Novavax (NASDAQ:NVAX)

Novavax, Inc. (Novavax) is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company through its recombinant nanoparticle vaccine technology produces vaccine candidates to respond to both known and newly emerging diseases. Its product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). Its lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, and including Middle East respiratory syndrome (MERS).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *